ArticleParasites & vectors2009
A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427.
Article in Parasites & vectors, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Past and future of trypanosomatids high-throughput phenotypic screening.Memorias do Instituto Oswaldo Cruz · 2022Article
- Sensitive quantification of α-glucans in mouse tissues, cell cultures, and human cerebrospinal fluid.The Journal of biological chemistry · 2020Article
- Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug Discovery.Genes · 2020Review
- The Antifungal Drug Isavuconazole Is both Amebicidal and Cysticidal against Acanthamoeba castellanii.Antimicrobial agents and chemotherapy · 2020Article
- Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays.PLoS neglected tropical diseases · 2018Article
- Inositol polyphosphate multikinase regulation of Trypanosoma brucei life stage development.Molecular biology of the cell · 2018Article
- The establishment of in vitro culture and drug screening systems for a newly isolated strain of Trypanosoma equiperdum.International journal for parasitology. Drugs and drug resistance · 2017Article
- Next-generation antimicrobials: from chemical biology to first-in-class drugs.Archives of pharmacal research · 2015Review
- New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.Scientific reports · 2015Article
- Development and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni.PLoS neglected tropical diseases · 2015Article
- Establishment of ATP-based luciferase viability assay in 96-well plate for Trypanosoma congolense.The Journal of veterinary medical science · 2014Article
- Computer-aided discovery of Trypanosoma brucei RNA-editing terminal uridylyl transferase 2 inhibitors.Chemical biology & drug design · 2014Article
- Luminescent multiplex viability assay for Trypanosoma brucei gambiense.Parasites & vectors · 2013Article
- Corifungin, a new drug lead against Naegleria, identified from a high-throughput screen.Antimicrobial agents and chemotherapy · 2012Article
- A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes.PLoS neglected tropical diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman African Trypanosomiasis (HAT) is caused by two trypanosome species, Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Current drugs available for the treatment of HAT have significant issues related to toxicity, administration regimes with limited effectiveness across species and disease stages, thus there is a considerable need to find alternative drugs. A well recognised approach to identify new drug candidates is high throughput screening (HTS) of large compound library collections.
resultsWe describe here the development of a luciferase based viability assay in 384-well plate format suitable for HTS of T.b.brucei. The parameters that were explored to determine the final HTS assay conditions are described in detail and include DMSO tolerability, Z', diluents and cell inoculum density. Reference compound activities were determined for diminazene, staurosporine and pentamidine and compared to previously published IC50 data obtained. The assay has a comparable sensitivity to reference drugs and is more cost effective than the 96-well format currently reported for T.b.brucei.
conclusionDue to the reproducibility and sensitivity of this assay it is recommended for potential HTS application. As it is commercially available this assay can also be utilised in many laboratories for both large and small scale screening.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.